Clinical development of novel therapeutics for castration-resistant prostate cancer

Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer

(2012) M. L. Huber et al.   JNCI-Journal of the National Cancer Institute

Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth

(2011) David J. Mulholland et al.   CANCER CELL

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

(2011) Brett S. Carver et al.   CANCER CELL

The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature

(2011) Guru Sonpavde et al.   EUROPEAN UROLOGY

Androgen Receptor Rediscovered: The New Biology and Targeting the Androgen Receptor Therapeutically

(2011) Charles J. Ryan et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer

(2011) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice

(2011) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone

(2011) Eleni Efstathiou et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab

(2011) D. Castellano et al.   ONCOLOGIST

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer

(2010) Daniel C. Danila et al.   JOURNAL OF CLINICAL ONCOLOGY

Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

(2010) Alison H.M. Reid et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

(2010) Howard I Scher et al.   LANCET

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II study of sunitinib in men with advanced prostate cancer

(2009) M. Dror Michaelson et al.   ANNALS OF ONCOLOGY

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

(2009) Celestia S. Higano et al.   CANCER

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

(2009) A. C. Mita et al.   CLINICAL CANCER RESEARCH

Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

(2009) C. Tran et al.   SCIENCE

Predictive Value of Plasma Hepatocyte Growth Factor/Scatter Factor Levels in Patients with Clinically Localized Prostate Cancer

(2008) A. Gupta et al.   CLINICAL CANCER RESEARCH

Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study

(2008) D. R. Berthold et al.   CLINICAL CANCER RESEARCH

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

(2008) Gerhardt Attard et al.   JOURNAL OF CLINICAL ONCOLOGY